Document Detail


Nanodelivery in airway diseases: challenges and therapeutic applications.
MedLine Citation:
PMID:  19616124     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
FROM THE CLINICAL EDITOR: Therapeutic applications of nano-delivery in airway diseases involve targeted delivery of DNA, siRNA, drugs or peptides to hematopoietic progenitor cells and pulmonary epithelium. These nano-particles must be biodegradable, capable of providing sustained drug delivery to specific cells, and should escape the endocytic degradation machinery. For effective gene-delivery they should also provide nuclear entry and chromosomal integration.
Authors:
Indrajit Roy; Neeraj Vij
Related Documents :
18808304 - Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for in...
17622984 - Mechanisms and classifications of chronic obstructive pulmonary disease: a literature r...
10556174 - Novel approaches and targets for treatment of chronic obstructive pulmonary disease.
9893764 - An increase of soluble fas, an inhibitor of apoptosis, associated with progression of c...
6680314 - The modification of morton's complex segregation analysis.
24503004 - Ageing and parkinson's disease: why is advancing age the biggest risk factor?
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2009-07-16
Journal Detail:
Title:  Nanomedicine : nanotechnology, biology, and medicine     Volume:  6     ISSN:  1549-9642     ISO Abbreviation:  Nanomedicine     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-30     Completed Date:  2010-06-30     Revised Date:  2014-09-21    
Medline Journal Info:
Nlm Unique ID:  101233142     Medline TA:  Nanomedicine     Country:  United States    
Other Details:
Languages:  eng     Pagination:  237-44     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Drug Carriers / chemistry*
Genetic Therapy / methods*
Humans
Lung Diseases / therapy*
Nanostructures / administration & dosage*,  chemistry*
Grant Support
ID/Acronym/Agency:
R03 HL096931/HL/NHLBI NIH HHS; R03 HL096931-01/HL/NHLBI NIH HHS; R03 HL096931-02/HL/NHLBI NIH HHS; RHL096931//PHS HHS; UL RR 025005/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Drug Carriers
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to canc...
Next Document:  Simultaneous detection of dopamine, ascorbic acid, and uric acid at electrochemically pretreated car...